TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

European journal of molecular biology and biochemistry

Volume 11, Issue 1, 2024
Mcmed International
European journal of molecular biology and biochemistry
Issn
2348 - 2192 (Print), 2348 - 2206 (Online)
Frequency
bi-annual
Email
editorejmbb@mcmed.us
Journal Home page
http://mcmed.us/journal/ejmbb
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
ADROPIN LEVELS IN BETA-THALASSEMIA MAJOR PATIENTS ARE ASSOCIATED WITH INSULIN RESISTANCE
Author
Dr. K Amaranth Reddy*, Dr. Sivakumar
Email
Amaranth@gmail.com
keyword
Adropin, insulin-resistant, beta-thalassemia
Abstract
A study based on serum level of adropin in beta-thalassemia major patients suggested that these people were insulin-resistant. In a cross-sectional study, people with beta-thalassemia major undergoing regular transfusion and chelation therapy were studied. Measures of glucose metabolism, including glycated hemoglobin (HbA1c) and insulin levels, were assessed for fasting serum samples. It has been found that serum adropin levels and insulin resistance markers are significantly correlated among patients diagnosed with betathalassemia major. In comparison with fasting glucose, insulin, HOMA-IR, and HbA1c levels, higher levels of adropin were associated with better glucose control and lower insulin resistance. In multiple linear regression analysis taking into account potential confounding factors, age, sex, and body mass index were significantly associated. Due to its role in preventing insulin resistance development and progression, adropin may be an effective therapeutic target for beta-thalassemia major patients. Adropin could be an effective therapeutic target for insulin resistance in beta-thalassemia major patients, but additional research is necessary to confirm these results
Download Broucher
Back to Top >>>>